Publicaciones en las que colabora con Marta Benavent Viñuales (20)

2024

  1. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74

2023

  1. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  2. Hemicolectomy versus appendectomy for patients with appendiceal neuroendocrine tumours 1–2 cm in size: a retrospective, Europe-wide, pooled cohort study

    The Lancet Oncology, Vol. 24, Núm. 2, pp. 187-194

  3. MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms

    Molecular Oncology, Vol. 17, Núm. 4, pp. 582-597

2022

  1. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

2021

  1. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial

    Oncologist, Vol. 26, Núm. 11, pp. 941-949

  2. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

    Pancreatology, Vol. 21, Núm. 1, pp. 215-223

2020

  1. The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407)

    Oncologist, Vol. 25, Núm. 9, pp. 745-e1265

2019

  1. Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)

    British Journal of Cancer, Vol. 121, Núm. 7, pp. 537-544

  2. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  3. SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 55-63

2018

  1. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432

  2. Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial

    Endocrine-Related Cancer, Vol. 25, Núm. 3, pp. 309-322

2017

  1. Prognostic relevance of Src activation in stage II-III colon cancer

    Human Pathology, Vol. 67, pp. 119-125

2015

  1. Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer

    Oncotarget, Vol. 6, Núm. 8, pp. 6151-6159

  2. Safety and activity of the first-in-class Sym004 anti-EGFR antibody mixture in patients with refractory colorectal cancer

    Cancer Discovery, Vol. 5, Núm. 6, pp. 598-609

2014

  1. MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer

    BMC Cancer, Vol. 14, Núm. 1

  2. New anticancer agents in neuroendocrine tumors

    Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach (Springer-Verlag Paris), pp. 181-198

  3. Prognostic relevance of estrogen receptor-α Ser167 phosphorylation in stage II-III colon cancer patients

    Human Pathology, Vol. 45, Núm. 12, pp. 2437-2446

2012

  1. New targeted agents in gastroenteropancreatic neuroendocrine tumors

    Targeted Oncology, Vol. 7, Núm. 2, pp. 99-106